BGI Genomics Co. Ltd. Class A 300676
SZSE · China · Health Technology
CNY 45.86+1.70 (+3.85%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
The global NICU genetic testing market is forecast to grow from USD 1.74 billion in 2026 to USD 4.80 billion by 2036, at a 10.67% CAGR. Growth is driven by rising neonatal genetic disorders, rapid whole genome and exome sequencing, next-generation sequencing, chromosomal microarrays and personalized neonatal care. North America leads the market, while Asia-Pacific is expected to grow fastest. The report analyzes key trends, technologies, segments, regional opportunities and leading companies, in
Commemorating BGI Group's 27th anniversary, BGI Genomics today introduced its Digital Life Twin framework alongside an advanced multi-omics diagnostic portfolio at the 2026 Global New Product Launch Event. Grounded in over two decades of population-scale genetic discoveries, the launch marks a decisive transition from traditional, reactive diagnostics to continuous, predictive health management across the entire human lifecycle.
The HGP2 Rare Disease Alliance of the Asia-Pacific Region (HGP2 RaDiAnce–APAC) was officially launched in Kuala Lumpur on May 10.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.